calendar
7,405 catalysts · 3,350 8k filing · 1,080 grant · 1,000 device adverse event · 579 earnings · 519 approval · 408 device 510k
7,405 catalysts · 3,350 8k filing · 1,080 grant · 1,000 device adverse event · 579 earnings · 519 approval · 408 device 510k
Sponsor: AUROBINDO PHARMA LTD. Form: FOR SOLUTION. Route: ORAL
Icosapent Ethyl Capsules, 1 gram, 120 Capsules per bottle, Rx only, Manufactured by: Softgel Healthcare Pvt. Ltd., India; Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534. NDC: 70710-1592-7 — Reason: Failed Tablet/Capsule specifications: Red dots inside capsule and melted capsule caused by oxidized Icosapent ethyl, the active ingredient. — Status: Ongoing
Product code: MGZ. Advisory committee: Cardiovascular. Type: Special
Product code: MUJ. Advisory committee: Radiology. Type: Traditional
Product code: FXX. Advisory committee: General, Plastic Surgery. Type: Traditional
Product code: HWC. Advisory committee: Orthopedic. Type: Traditional
Product code: IYE. Advisory committee: Radiology. Type: Traditional
Product code: HSB. Advisory committee: Orthopedic. Type: Traditional
Product code: OLO. Advisory committee: Neurology. Type: Traditional
Product code: FMI. Advisory committee: General Hospital. Type: Traditional
Product code: LBH. Advisory committee: Dental. Type: Traditional
Product code: HJO. Advisory committee: Ophthalmic. Type: Traditional
Supplement type: 30-Day Notice. Product code: EZW. Advisory committee: GU. Decision: OK30
Supplement type: 30-Day Notice. Product code: LMH. Advisory committee: SU. Decision: OK30
Supplement type: Normal 180 Day Track. Product code: LWP. Advisory committee: CV. Decision: APPR
Supplement type: 30-Day Notice. Product code: QON. Advisory committee: GU. Decision: OK30
Supplement type: 30-Day Notice. Product code: LNM. Advisory committee: GU. Decision: OK30
Supplement type: 30-Day Notice. Product code: LMH. Advisory committee: SU. Decision: OK30
Supplement type: 30-Day Notice. Product code: LPM. Advisory committee: OP. Decision: OK30
Product code: MNQ. Advisory committee: AN. Decision: APPR
Supplement type: 30-Day Notice. Product code: HQL. Advisory committee: OP. Decision: OK30
EB grant. $21,072. PI: Thomas Chan
HD grant. $527,648. PI: Maya Rosen
DK grant. $612,587. PI: Noelle Elizabeth Younge
AG grant. $51,038. PI: Emily Navarrete
GM grant. $423,352. PI: Kai Li
GM grant. $412,124. PI: Shinuo Weng
CA grant. $410,933. PI: STEVEN F DOWDY
DK grant. $664,240. PI: Isin Cakir
GM grant. $554,945. PI: Douglas W Leaman
CA grant. $658,492. PI: Song Li
DK grant. $25,000. PI: Mike Henne
EB grant. $21,600. PI: Reem Khojah
CA grant. $593,557. PI: Lawrence D Recht
CA grant. $411,334. PI: Amber Simmons Kleckner
Sponsor: ABBVIE. Form: SUSPENSION. Route: ENTERAL
Sponsor: ACTAVIS LABS FL INC. Form: TABLET. Route: ORAL
Sponsor: I3 PHARMS. Form: CAPSULE. Route: ORAL
Sponsor: ORION PHARMA. Form: TABLET. Route: ORAL
Sponsor: ABBVIE. Form: SOLUTION. Route: SUBCUTANEOUS
Sponsor: NOVO. Form: TABLET. Route: ORAL
Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: INJECTION
Sponsor: MICRO LABS. Form: FOR SOLUTION. Route: ORAL
Sponsor: NOVO. Form: SOLUTION. Route: SUBCUTANEOUS
Sponsor: DEPROCO. Form: SOLUTION. Route: INJECTION
Sponsor: AVION PHARMS. Form: TABLET. Route: ORAL
Sponsor: IMPAX. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL
Sponsor: AUROLIFE PHARMA LLC. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL
Sponsor: AUROLIFE PHARMA LLC. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL
Sponsor: AUROLIFE PHARMA LLC. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL